Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
For the full year,net profit rose 105.08% to Rs 348.91 crore in the year ended March 2026 as against Rs 170.13 crore during the previous year ended March 2025. Sales rose 29.38% to Rs 2192.49 crore in the year ended March 2026 as against Rs 1694.57 crore during the previous year ended March 2025.
Sai Life Sciences Ltd, Apollo Tyres Ltd, Muthoot Finance Ltd, Chambal Fertilisers & Chemicals Ltd are among the other stocks to see a surge in volumes on BSE today, 15 May 2026.
Sheela Foam Ltd registered volume of 2.34 lakh shares by 10:47 IST on BSE, a 25.65 fold spurt over two-week average daily volume of 9114 shares. The stock rose 17.26% to Rs.637.60. Volumes stood at 8681 shares in the last session.
Sai Life Sciences Ltd saw volume of 2.47 lakh shares by 10:47 IST on BSE, a 6.17 fold spurt over two-week average daily volume of 40034 shares. The stock dropped 9.57% to Rs.1,006.55. Volumes stood at 83248 shares in the last session.
Apollo Tyres Ltd witnessed volume of 4.46 lakh shares by 10:47 IST on BSE, a 5.39 times surge over two-week average daily volume of 82808 shares. The stock dropped 0.07% to Rs.401.40. Volumes stood at 54826 shares in the last session.
Muthoot Finance Ltd witnessed volume of 1.68 lakh shares by 10:47 IST on BSE, a 5.21 times surge over two-week average daily volume of 32214 shares. The stock dropped 4.35% to Rs.3,375.35. Volumes stood at 60941 shares in the last session.
Chambal Fertilisers & Chemicals Ltd notched up volume of 1.98 lakh shares by 10:47 IST on BSE, a 4.79 fold spurt over two-week average daily volume of 41259 shares. The stock rose 3.73% to Rs.440.65. Volumes stood at 42523 shares in the last session.
Profit after tax stood at Rs 100 crore in Q3 FY26, compared with Rs 54 crore a year ago, translating into an 86% YoY increase. PAT margin improved to 18% from 12% in the corresponding quarter last year.
Profit before tax surged 87% YoY to Rs 134 crore in Q3 FY26 from Rs 72 crore in the year-ago quarter.
EBITDA increased 54% YoY to Rs 191 crore from Rs 124 crore in Q3 FY25, while EBITDA margin expanded to 34% from 28%. The growth was supported by improved capacity utilization, operational efficiencies, and ongoing cost optimization initiatives.
Sai Life Sciences said it has invested Rs 405 crore in capital expenditure so far, against a planned capex outlay of Rs 700 crore for FY26, in line with its long-term strategy to strengthen capabilities and expand capacity.
During the quarter, it successfully completed eight customer audits across its manufacturing and R&D units, with zero data integrity deviations and no critical observations reported.
Krishna Kanumuri, managing director and CEO, Sai Life Sciences, said: 'Q3 FY26 marked continued progress in building Sai Life Sciences into a science-led, globally relevant CRDMO. Looking ahead, we remain confident in sustaining our growth momentum in the coming year. With disciplined execution and a clear strategic direction, Sai Life Sciences is well positioned to support the next phase of innovation while creating long-term value for all stakeholders.'
Hyderabad-based Sai Life Sciences is one of India’s fastest growing Contract Research, Development, and Manufacturing Organizations (CRDMO) that partners with innovator pharmaceutical and biotech companies to accelerate the discovery, development, and commercialization of new medicines.